People Briefs: Changes At DexCom, Insulet, MITA And More
This article was originally published in The Gray Sheet
Executive Summary
DexCom promotes Kevin Sayer to CEO post, while its diabetes collaborator Insulet makes multiple changes at the VP level. The Medical Imaging & Technology Alliance names policy director, and more.
You may also be interested in...
FDA Approves Animas’ Vibe Linking Insulin Pump With DexCom CGM
The insulin pump is the first FDA-approved device featuring Dexcom’s G4 Platinum sensing technology; it allows patients to see glucose data and administer insulin directly from the pump.
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.
For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion
After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.